Compagnie Lombard Odier SCmA’s ImmunityBio IBRX Stock Holding History

Compagnie Lombard Odier SCmA’s Portfolio IBRX Stock Details IBRX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2024 Q1	–	Sell	-14,000	Closed	-$63.4K	–	536
2023 Q4	$70.3K	Hold	14,000	–	–	﹤0.01%	384
2023 Q3	$23.7K	Hold	14,000	–	–	﹤0.01%	476
2023 Q2	$38.9K	Hold	14,000	–	–	﹤0.01%	432
2023 Q1	$25.5K	Hold	14,000	–	–	﹤0.01%	504
2022 Q4	$71K	Hold	14,000	–	–	﹤0.01%	434
2022 Q3	$70K	Hold	14,000	–	–	﹤0.01%	431
2022 Q2	$52K	Hold	14,000	–	–	﹤0.01%	432
2022 Q1	$79K	Buy	+14,000	New	+$85.9K	﹤0.01%	403

Other funds holding IBRX

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Credit Suisse Zurich, Switzerland $104B AUM 34.76% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return

Rafferty Asset Management New York $24.6B AUM 47.06% 1-Year Est. Return

Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return

Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return

Compagnie Lombard Odier SCmA's IBRX Position: Q1 2024 in Review

Compagnie Lombard Odier SCmA sold out of ImmunityBio (IBRX) in Q1 2024, closing a stake of 14,000 shares — an estimated $63.4K sold.

Compagnie Lombard Odier SCmA first reported a position in IBRX in Q1 2022 and held it in 8 quarters. The position peaked at $79K in Q1 2022. 165 funds tracked by Wall St. Rank hold IBRX as of Q1 2024.

Compagnie Lombard Odier SCmA reported no remaining ImmunityBio position as of Q1 2024 after selling out during the quarter.
Compagnie Lombard Odier SCmA sold 14,000 ImmunityBio shares in Q1 2024, an estimated $63.4K.
Compagnie Lombard Odier SCmA first reported a position in ImmunityBio in Q1 2022 and held it in 8 quarters.
Compagnie Lombard Odier SCmA's ImmunityBio position peaked at $79K in Q1 2022.
165 funds tracked by Wall St. Rank held ImmunityBio as of Q1 2024.

Based on Compagnie Lombard Odier SCmA's 13F filing for Q1 2024, filed 1 May 2024.